We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+11.74%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$252M
AUM Growth
-$86.3M
(-26%)
Cap. Flow
-$109M
Cap. Flow
% of AUM
-43.42%
Top 10 Holdings %
Top 10 Hldgs %
38.06%
Holding
113
New
35
Increased
12
Reduced
16
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESRX
Express Scripts Holding Company
ESRX
|
+$11M |
| 2 |
Labcorp
LH
|
+$9.27M |
| 3 |
Merck
MRK
|
+$8.29M |
| 4 |
LivaNova
LIVN
|
+$7.92M |
| 5 |
ATHN
Athenahealth, Inc.
ATHN
|
+$5.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$10.7M |
| 2 |
BCR
CR Bard Inc.
BCR
|
+$9.32M |
| 3 |
GSK
GSK
|
+$8.25M |
| 4 |
UnitedHealth
UNH
|
+$7.79M |
| 5 |
Centene
CNC
|
+$7.73M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.96% |
| 2 | Industrials | 2.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EVHC
1
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $11.7M | 4.66% |
187,200
+47,200
| +34% | +$2.72M |
|
2
Boston Scientific
BSX
$68.5B
| $11.7M | 4.63% |
420,546
+55,546
| +15% | +$1.47M |
|
|
ESRX
3
DELISTED
Express Scripts Holding Company
ESRX
| $11.2M | 4.43% |
+174,700
| New | +$11M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $10.7M | 4.26% |
88,112
+20,612
| +31% | +$2.4M |
|
|
5
Labcorp
LH
$25.8B
| $10M | 3.98% |
+75,660
| New | +$9.27M |
|
|
6
LivaNova
LIVN
$4.51B
| $8.57M | 3.4% |
+140,002
| New | +$7.92M |
|
|
7
Merck
MRK
$326B
| $8.33M | 3.31% |
+136,240
| New | +$8.29M |
|
|
8
PUT
Merck
MRK
$326B
| $8.33M | 3.31% |
+136,240
| New | +$8.29M |
|
9
ICU Medical
ICUI
$4.14B
| $7.76M | 3.08% |
45,000
-5,000
| -10% | -$802K |
|
10
Baxter International
BAX
$12.6B
| $7.57M | 3% |
125,000
-55,000
| -31% | -$3.12M |
|
11
CALL
AstraZeneca
AZN
$267B
| $6.82M | 2.71% |
+100,000
| New | +$6.53M |
|
|
IVC
12
DELISTED
Invacare Corporation
IVC
| $6.67M | 2.65% |
505,000
-20,010
| -4% | -$263K |
|
13
Globus Medical
GMED
$10.9B
| $6.63M | 2.63% |
200,000
-85,646
| -30% | -$2.69M |
|
|
NSTG
14
DELISTED
NanoString Technologies, Inc.
NSTG
| $6.59M | 2.61% |
398,206
+255,456
| +179% | +$4.51M |
|
|
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.55M | 2.6% |
70,000
+38,750
| +124% | +$2.37M |
|
|
16
CALL
Merck
MRK
$326B
| $6.41M | 2.54% |
+104,800
| New | +$6.38M |
|
|
ATHN
17
DELISTED
Athenahealth, Inc.
ATHN
| $6.04M | 2.4% |
+43,000
| New | +$5.37M |
|
|
NXTM
18
DELISTED
NxStage Medical Inc.
NXTM
| $5.56M | 2.21% |
221,685
-53,315
| -19% | -$1.32M |
|
|
XENT
19
DELISTED
Intersect ENT, Inc
XENT
| $5.52M | 2.19% |
197,498
-190,424
| -49% | -$4.31M |
|
|
PRAH
20
DELISTED
PRA Health Sciences, Inc.
PRAH
| $5.44M | 2.16% |
+72,500
| New | +$5.03M |
|
|
QGENF
21
DELISTED
QIAGEN NV
QGENF
| $5.26M | 2.09% |
156,900
+4,400
| +3% | +$148K |
|
22
Bio-Rad Laboratories Class A
BIO
$8.86B
| $5.16M | 2.05% |
22,820
-30,180
| -57% | -$6.58M |
|
|
ABCO
23
DELISTED
Advisory Board Co
ABCO
| $5.15M | 2.04% |
+100,000
| New | +$5.01M |
|
24
CALL
Intuitive Surgical
ISRG
$130B
| $4.68M | 1.86% |
+45,000
| New | +$4.32M |
|
|
EXAS
25
DELISTED
Exact Sciences
EXAS
| $4.42M | 1.76% |
125,000
-225,000
| -64% | -$6.94M |
|
Similar funds
GMP
BCA
ONGA
RC
CVV
DOFI
SRA
SR
Pura Vida Investments's Q2 2017 Portfolio in Review
As of Q2 2017, Pura Vida Investments held 113 positions worth $252M, down 26% from $338M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Pura Vida Investments withdrew a net $109M in Q2 2017, closing 45 positions and reducing 16 holdings. Its most notable exit was Hologic, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 74% a quarter earlier, followed by Industrials.
Against the trend, Pura Vida Investments opened a new position in Express Scripts Holding Company worth $11.2M.
- Pura Vida Investments's largest Q2 2017 buy was Express Scripts Holding Company: 174,700 shares worth $11.2M.
- Pura Vida Investments added most to NanoString Technologies, Inc. in Q2 2017, an estimated $4.51M increase.
- Pura Vida Investments's biggest Q2 2017 reduction was Exact Sciences, cutting an estimated $6.94M.
- Pura Vida Investments fully exited Hologic in Q2 2017, selling an estimated $10.7M.
- Pura Vida Investments's ten largest holdings make up 38% of its $252M portfolio in Q2 2017.
- Pura Vida Investments opened 35 new positions and closed 45 in Q2 2017.
- Pura Vida Investments's portfolio value fell 26% quarter-over-quarter to $252M.
Based on Pura Vida Investments's 13F filing for Q2 2017, filed 14 Aug 2017.